Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...
GlobalData on MSN
Eli Lilly buys Adverum in eye disease gene therapy punt
Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...
Eli Lilly and Company has agreed to acquire Adverum Biotechnologies Inc., a clinical-stage company pioneering the use of intravitreal gene therapy.
Eli Lilly plans to acquire a gene therapy developer that once planned a 200-job facility in Research Triangle Park.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the ...
17h
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest ...
Eli Lilly and Company and Adverum Biotechnologies, a clinical-stage gene therapy company aiming to preserve sight for life in ...
Zacks Investment Research on MSN
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...
US markets wrapped up the week on a high note, with strong earnings and cooling inflation data propelling both major indices to new records. The S&P 500 broke 6 800 for the first time with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback